Price (90d)
No price history yet — the daily price refresh runs once a day.
Signal Score (90d)
100Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $822.31M | $-92.19M | $-2.28 |
| 2024 | $799.49M | $-126.00M | $-3.30 |
| 2023 | $746.64M | $-151.40M | $-4.12 |
| 2022 | $460.71M | $-19.75M | $-0.98 |
| 2021 | $464.48M | $-38.38M | $-1.95 |
Social Signal Score
Earnings
Tue, Nov 3(in 3 months)
Consensus estimate $0.08 per share
Typical surprise +52.9% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Aug 5$-0.39 vs $-0.41beat
- Tue, May 5$-0.52 vs $-0.68beat
- Tue, Feb 24$-0.06 vs $-0.19beat
- Tue, Nov 4$0.20 vs $0.12beat
- Tue, Aug 5$0.13 vs $0.04beat
- Tue, May 6$-0.08 vs $-0.17beat
Estimates and results for OFIX via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Valuation
OFIXhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Mentions (1)
- Newsmarketbeat.com·5h ago·Neutral
Orthofix Medical Sees Reimbursement Rebound, but Spine Slump Clouds Outlook Orthofix Medical NASDAQ: OFIX executives said the company's updated outlook reflects the restoration of bone growth stimulation reimbursement, improving trends in biologics and limb reconstruction, and an expected European inventory order, partly offset by a steeper-than-anticipated decline among smaller U.S. spine distributors.
View source ↗